Navigation Links
Misonix Announces New Distribution Agreement for Portugal
Date:4/13/2009

FARMINGDALE, N.Y., April 13 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with Ekrior Lda, a Division of Avanco Sistemas Medicos, based in Barcarena, Portugal, for the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator, the BoneScalpel(TM) Ultrasonic Bone Cutter, and the SonicOne(R) Ultrasonic Wound Debrider. The agreement provides Ekrior with the rights to sell in Portugal, and includes minimum purchase requirements.

Ekrior is growing rapidly in the Portuguese market, largely by building a reputation as a distributor of state-of-the-art medical devices and capital equipment, with special emphasis on radiation oncology and specialized surgery.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix welcomes Ekrior to our growing family of distribution partnerships in Europe. We know Ekrior as a high-profile distributor of advanced technology products in Portugal," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Ekrior has a reputation as a high integrity sales organization and is well known for successfully introducing high tech medical devices to their markets. We are particularly pleased that they will be distributing three of our product platforms through their well established distribution system."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
2. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
3. Misonix Announces New Sales Agency Agreement for Eastern Europe
4. Misonix Announces New Distribution Agreement for Israel
5. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
6. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
7. Misonix Announces New HIFU Distribution Agreement for Italy
8. Misonix Announces Extension and Expansion of Distribution Agreement With Mentor Corporation
9. Misonix Reports First Quarter Fiscal Year 2009 Financial Results
10. Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern
11. Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... 2017 , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been ... (SLMBNI), part of Saint Luke’s Health System . Dr. Upadhyaya has served in ... M.Sc., FAANS joins Stanley P. Fisher, M.D., who has served as medical ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Cosmetic Town, ... doctors and the cosmetic surgeries they perform on a daily basis. , The ... cosmetic surgery procedures they specialize in at their practices. , When asked about ...
(Date:7/24/2017)... Hagerstown, MD (PRWEB) , ... July 24, 2017 ... ... County Public Schools (MCPS) have partnered together for a unique opportunity that helps high ... their mission of “Removing Barriers, Creating Opportunities.” Horizon Goodwill will host over ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... $1,000 total in scholarship awards to be awarded annually to and divided between ... an interest in bringing awareness to Amazonian plant medicine. To apply for the ...
(Date:7/24/2017)... ... 2017 , ... Every year, thousands of dedicated Higher Education and K12 professionals ... is coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)... July 24, 2017 IBM (NYSE: IBM ) ... Quadrant for Solid-State Arrays (SSA) for the fourth year in ... According to Gartner, "Vendors in the Leaders quadrant have the ... Vision. A vendor in the Leaders quadrant has the market ... the acceptance of new technologies. These vendors demonstrate a clear ...
(Date:7/21/2017)... SILVER SPRING, Md. and RESEARCH ... -- United Therapeutics Corporation (NASDAQ: UTHR ) ... 2017 financial results before the market opens on Thursday, ... United Therapeutics will host a teleconference on Thursday, July ... is accessible by dialing 1-877-351-5881, with international callers dialing ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
Breaking Medicine Technology: